Benzinga | Jan 24, 2022 07:54AM EST

Morgan Stanley Maintains Overweight on Eli Lilly, Lowers Price Target to $272

Morgan Stanley analyst David Risinger maintains Eli Lilly (NYSE:LLY) with a Overweight and lowers the price target from $275 to $272.